In this review:
AVATAR supports early intervention for asymptomatic severe AS
Myocardial energetic impairment may cause pulmonary congestion in HFpEF
Dapagliflozin attenuates increases in hsTnT in HFrEF
CG-based deep learning improves prognostication of incident AF
Empagliflozin efficacious for HFpEF regardless of baseline health status
CHIEF-HF: canagliflozin improves health status regardless of ejection fracture status
Both dabigatran and warfarin protect against cognitive decline in older adults with AF
Long-term low-dose aspirin does not prevent dementia
EMPULSE finds empagliflozin beneficial for HF in the acute setting
Promising cholesterol-lowering results for the first oral PCSK9 inhibitor
Finerenone reduces risk of new-onset HF in patients with CKD and T2D
Please login below to download this issue (PDF)